Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220958 | 0.84 | KMT2A (0.50) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL14427590 | 0.84 | APAF1 (0.56) | TP53MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2194087 | 0.84 | KMT2A (0.52) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL2193749 | 0.78 | NPC1 (0.45) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL2194340 | 0.78 | MEN1 (0.46) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL3585422 | 0.76 | MEN1 (0.61) | TP53MEN1KMT2APABPC1SMN1; SMN2 | |
| SCHEMBL13571733 | 0.76 | MEN1 (0.49) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL2192568 | 0.76 | TP53 (0.42) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL2218436 | 0.75 | MEN1 (0.44) | TP53MEN1KMT2APABPC1ALDH1A1 | |
| SCHEMBL15157728 | 0.75 | ALDH1A1 (0.48) | TP53MEN1KMT2APABPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | TP53 4/4885MEN1 1121/4885KMT2A 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.